Veledimex racemate NEW
| Price | $1970 | $2580 | $3400 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-17 |
Product Details
| Product Name: Veledimex racemate | CAS No.: 755013-59-3 |
| Supply Ability: 10g | Release date: 2025/07/17 |
Product Introduction
Bioactivity
| Name | Veledimex racemate |
| Description | Veledimex racemate, the racemic form of veledimex, is an orally available, small-molecule ligand that activates the RheoSwitch Therapeutic System. |
| In vitro | Interleukin 12 (IL-12) is a pro-inflammatory cytokine essential for stimulating anti-cancer immune responses. Ad-RTS-IL-12 is an adenovirus vector designed to express hIL-12. Veledimex, an orally active small molecule diacylhydrazine, controls the expression of target genes, with gene product levels and duration of action dependent on veledimex dose and administration timing. |
| In vivo | In murine models of melanoma, breast cancer, and glioma, the combined intratumoral injection of Ad-RTS-mIL-12 and oral dose of veledimex has shown to produce a dose-dependent antitumor effect. This response is associated with increased veledimex levels in plasma and tumor tissues. Notably, this combination therapy leads to a dose-responsive activation of IL-12 mRNA (switch on) and subsequent elevations of IL-12p70 within the tumor, while only minimally increasing its levels in the serum. Enhanced tumor levels of IL-12 are linked with an upsurge in CD8+ cytotoxic T cells and a reduction in regulatory T cells within the tumor microenvironment. Consequently, this regimen achieves dose-dependent reductions in tumor growth rates without significantly affecting body weight in both breast and melanoma syngeneic mouse models. Veledimex exhibits moderate to low oral bioavailability (-56% in mice and up to 17.4% in cynomolgus monkeys), alongside relatively low plasma clearance (1399 mL/h/kg in mice and 1170 mL/h/kg in monkeys), a high volume of distribution (20271 mL/kg in mice and 9180 mL/kg in monkeys), and prolonged terminal half-lives (-10 hours in mice and -30 hours in monkeys), following single oral or intravenous administrations. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Veledimex racemate |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-19 | |
| $59.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-06-12 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $2580.00/50mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY